TNFRSF17 and plasma cell myeloma: Additionally, idecabtagene vicleucel (Abecma) and ciltacabtagene autoleucel (Carvykti), targeting B-cell maturation antigen (BCMA), have shown significant clinical benefits in patients with multiple myeloma (8–10).